Arlington Financial Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.49M | Sell |
43,432
-306
| -0.7% | -$40.3K | 0.7% | 33 |
|
|
2026
Q1 | $6.1M | Sell |
43,738
-1,383
| -3% | -$194K | 0.87% | 30 |
|
|
2025
Q4 | $5.54M | Buy |
45,121
+387
| +0.9% | +$47K | 0.79% | 32 |
|
|
2025
Q3 | $4.97M | Buy |
44,734
+747
| +2% | +$84.9K | 0.73% | 34 |
|
|
2025
Q2 | $4.88M | Sell |
43,987
-2,552
| -5% | -$272K | 0.8% | 32 |
|
|
2025
Q1 | $5.21M | Sell |
46,539
-481
| -1% | -$49.6K | 0.92% | 30 |
|
|
2024
Q4 | $4.34M | Buy |
47,020
+915
| +2% | +$82.4K | 0.86% | 35 |
|
|
2024
Q3 | $3.87M | Buy |
46,105
+64
| +0.1% | +$4.88K | 0.79% | 35 |
|
|
2024
Q2 | $3.16M | Buy |
46,041
+1,240
| +3% | +$82.8K | 0.69% | 37 |
|
|
2024
Q1 | $3.28M | Buy |
44,801
+1,678
| +4% | +$129K | 0.72% | 37 |
|
|
2023
Q4 | $3.49M | Buy |
43,123
+39
| +0.1% | +$3.04K | 1.04% | 31 |
|
|
2023
Q3 | $3.23M | Buy |
43,084
+341
| +0.8% | +$26.2K | 1.14% | 28 |
|
|
2023
Q2 | $3.29M | Buy |
42,743
+2
| +0% | +$160 | 1.2% | 26 |
|
|
2023
Q1 | $3.55M | Sell |
42,741
-6,442
| -13% | -$534K | 1.37% | 20 |
|
|
2022
Q4 | $4.22M | Sell |
49,183
-171
| -0.3% | -$13.5K | 1.78% | 16 |
|
|
2022
Q3 | $3.04M | Sell |
49,354
-3,464
| -7% | -$218K | 1.55% | 19 |
|
|
2022
Q2 | $3.27M | Buy |
52,818
+1,255
| +2% | +$77.7K | 1.47% | 18 |
|
|
2022
Q1 | $3.06M | Buy |
51,563
+148
| +0.3% | +$9.46K | 1.16% | 29 |
|
|
2021
Q4 | $3.73M | Buy |
51,415
+587
| +1% | +$40.4K | 1.26% | 23 |
|
|
2021
Q3 | $3.55M | Buy |
50,828
+201
| +0.4% | +$14.1K | 1.39% | 25 |
|
|
2021
Q2 | $3.49M | Buy |
50,627
+16,700
| +49% | +$1.12M | 1.32% | 26 |
|
|
2021
Q1 | $2.19M | Buy |
33,927
+26,438
| +353% | +$1.7M | 0.89% | 33 |
|
|
2020
Q4 | $436K | Sell |
7,489
-27,922
| -79% | -$1.68M | 0.18% | 51 |
|
|
2020
Q3 | $2.24M | Buy |
35,411
+229
| +0.7% | +$15.9K | 1.15% | 26 |
|
|
2020
Q2 | $2.71M | Buy |
35,182
+917
| +3% | +$70.3K | 1.53% | 20 |
|
|
2020
Q1 | $2.56M | Buy |
34,265
+7,658
| +29% | +$529K | 1.82% | 16 |
|
|
2019
Q4 | $1.73M | Sell |
26,607
-12,232
| -31% | -$797K | 0.96% | 31 |
|
|
2019
Q3 | $2.46M | Buy |
38,839
+906
| +2% | +$59.2K | 1.41% | 23 |
|
|
2019
Q2 | $2.56M | Buy |
37,933
+854
| +2% | +$56.2K | 1.47% | 22 |
|
|
2019
Q1 | $2.41M | Buy |
37,079
+3,773
| +11% | +$251K | 1.37% | 25 |
|
|
2018
Q4 | $2.08M | Sell |
33,306
-753
| -2% | -$52.6K | 0.89% | 35 |
|
|
2018
Q3 | $2.42M | Buy |
34,059
+174
| +0.5% | +$13.1K | 1.45% | 22 |
|
|
2018
Q2 | $2.64M | Buy |
33,885
+7,294
| +27% | +$515K | 1.53% | 20 |
|
|
2018
Q1 | $1.98M | Buy |
26,591
+440
| +2% | +$35K | 1.3% | 22 |
|
|
2017
Q4 | $2.13M | Buy |
+26,151
| New | +$1.99M | 1.01% | 25 |
|
Other funds holding GILD
LMFP
CIM
ATO
CGH
Arlington Financial Advisors's GILD Position: Q2 2026 in Review
Arlington Financial Advisors reduced its Gilead Sciences (GILD) stake by 0.7% in Q2 2026, selling an estimated $40.3K and leaving 43,432 shares worth $5.49M. The position accounts for 0.7% of the portfolio, ranked #33.
Arlington Financial Advisors first reported a position in GILD in Q4 2017 and has held it in 35 quarters since. The position peaked at $6.1M in Q1 2026. 690 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Arlington Financial Advisors held 43,432 shares of Gilead Sciences worth $5.49M as of Q2 2026.
- Arlington Financial Advisors sold 306 Gilead Sciences shares in Q2 2026, an estimated $40.3K.
- Gilead Sciences made up 0.7% of Arlington Financial Advisors's portfolio in Q2 2026, its #33 holding.
- Arlington Financial Advisors first reported a position in Gilead Sciences in Q4 2017 and has held it in 35 quarters since.
- Arlington Financial Advisors's Gilead Sciences position peaked at $6.1M in Q1 2026.
- 690 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Arlington Financial Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.